“Investors remain frustrated with the repeated R&D (research and development) failures,” said Abhishek Raval, an analyst at AlphaValue.
(Feb 12): Sanofi abruptly replaced chief executive officer Paul Hudson after a massive research spending boost failed to deliver rapid results, appointing Merck KGaA’s Belén Garijo to succeed him.
Hudson came under pressure as he tried to replace sales from a looming patent cliff for its top-selling asthma and skin disease drug Dupixent. The efforts didn’t succeed after a little over six years at the helm, with three key late-stage trials showing mixed or negative results last year.
